Tsuyoshi Fukuda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2622947/publications.pdf

Version: 2024-02-01

60 papers	1,568 citations	304701 22 h-index	315719 38 g-index
60 all docs	60 docs citations	60 times ranked	2234 citing authors

#	Article	IF	Citations
1	Testâ€dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for nonâ€malignant disorders. British Journal of Clinical Pharmacology, 2022, 88, 115-127.	2.4	5
2	Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing. Frontiers in Pediatrics, 2022, 10, 841051.	1.9	3
3	Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition. European Journal of Clinical Pharmacology, 2021, 77, 1157-1168.	1.9	5
4	Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. Journal of Clinical Pharmacology, 2021, 61, 857-870.	2.0	15
5	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology, 2021, 39, 797-806.	1.6	54
6	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 747-765.	3.3	1
7	Modelâ€informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. British Journal of Clinical Pharmacology, 2021, , .	2.4	8
8	A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. Bone Marrow Transplantation, 2021, 56, 3029-3031.	2.4	5
9	Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 429-439.	1.9	36
10	Next Challenge From the Variance in Individual Physiologicallyâ€Based Pharmacokinetic Modelâ€Predicted to Observed Morphine Concentration in Critically Ill Neonates. Clinical Pharmacology and Therapeutics, 2020, 107, 319-320.	4.7	3
11	Clinical Applications of Physiologically Based Pharmacokinetic Modeling: Perspectives on the Advantages and Challenges. Therapeutic Drug Monitoring, 2020, 42, 157-158.	2.0	10
12	Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. British Journal of Clinical Pharmacology, 2020, 86, 933-943.	2.4	9
13	Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. Journal of Clinical Pharmacology, 2020, 60, 453-465.	2.0	7
14	Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. Therapeutic Drug Monitoring, 2020, 42, 778-786.	2.0	10
15	Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. Journal of Clinical Pharmacology, 2020, 60, 992-998.	2.0	11
16	CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Bone Marrow Transplantation, 2020, 55, 1552-1559.	2.4	6
17	Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. Biology of Blood and Marrow Transplantation, 2019, 25, 2416-2421.	2.0	7
18	Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation, 2019, 19, 2944-2948.	4.7	77

#	Article	IF	Citations
19	A Theoretical Physiologicallyâ€Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 273-284.	2.5	30
20	Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Frontiers in Pediatrics, 2019, 7, 519.	1.9	3
21	Suggestions for Modelâ€Informed Precision Dosing to Optimize Neonatal Drug Therapy. Journal of Clinical Pharmacology, 2019, 59, 168-176.	2.0	22
22	Influence of <scp>OCT</scp>1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From <scp>PBPK</scp> Modeling and Clinical Study. Clinical Pharmacology and Therapeutics, 2019, 105, 761-768.	4.7	41
23	Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1651-1658.	3.0	6
24	Using a Vancomycin PBPK Model in Special Populations to Elucidate Caseâ€Based Clinical PK Observations. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 237-250.	2.5	18
25	Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clinical Pharmacokinetics, 2018, 57, 625-636.	3.5	11
26	PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 464-473.	2.5	33
27	Pharmacometric analysis of immunosuppressive drugs in pediatric transplant patients. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY52-3.	0.0	0
28	Pharmacometrics in children. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY35-2.	0.0	0
29	Characterizing important determinants of Tacrolimus pharmacokinetic variability in renal transplant patients: PBPK modeling approach using genotyped patients information. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR22-3.	0.0	0
30	Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. British Journal of Clinical Pharmacology, 2017, 83, 1097-1107.	2.4	14
31	Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. Biology of Blood and Marrow Transplantation, 2017, 23, 635-641.	2.0	24
32	Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. Clinical Pharmacokinetics, 2017, 56, 1207-1217.	3.5	12
33	Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatric Blood and Cancer, 2017, 64, e26470.	1.5	58
34	OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. Pharmacogenomics, 2017, 18, 621-629.	1.3	42
35	Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. European Journal of Pharmaceutical Sciences, 2017, 109, S124-S131.	4.0	39
36	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. Clinical Transplantation, 2017, 31, e12975.	1.6	23

#	Article	IF	Citations
37	Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children. Drug Metabolism and Disposition, 2017, 45, 23-26.	3.3	19
38	Fatty acid amide hydrolaseâ€“morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children. Pharmacogenomics, 2017, 18, 143-156.	1.3	11
39	Mycophenolate mofetilâ€related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs. Pediatric Transplantation, 2017, 21, e13033.	1.0	17
40	Drug Dosing in Obese Children. Pediatric Clinics of North America, 2017, 64, 1417-1438.	1.8	16
41	Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Journal of Antimicrobial Chemotherapy, 2017, 72, 254-260.	3.0	14
42	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Medicine, 2017, 14, e1002428.	8.4	29
43	Pharmacokinetics and pharmacogenomics of Î²-lactam-induced neutropenia. Pharmacogenomics, 2016, 17, 547-559.	1.3	7
44	A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Biology of Blood and Marrow Transplantation, 2016, 22, 1829-1835.	2.0	8
45	A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2220-2225.	2.0	18
46	Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 411-417.	2.5	19
47	Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 482-486.	2.0	37
48	Variable Eculizumab Clearance Requires PharmacodynamicÂMonitoring to Optimize TherapyÂforÂThrombotic Microangiopathy after HematopoieticÂStem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 307-315.	2.0	125
49	Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases. Blood, 2016, 128, 2203-2203.	1.4	3
50	Population pharmacokineticâ€“pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. Paediatric Anaesthesia, 2015, 25, 911-923.	1.1	24
51	The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologicallyâ€based pharmacokinetic model. British Journal of Clinical Pharmacology, 2015, 80, 1438-1446.	2.4	26
52	Kidney Injury Molecule-1 and its association with delayed clearance and drug exposure in pediatric oncology patients treated with high dose methotrexate.. Journal of Clinical Oncology, 2015, 33, 10034-10034.	1.6	0
53	Optimization of Mycophenolic Acid Therapy Using Clinical Pharmacometrics. Drug Metabolism and Pharmacokinetics, 2014, 29, 4-11.	2.2	22
54	Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantationâ€“Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2014, 20, 518-525.	2.0	218

#	Article	IF	Citations
55	OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics, 2013, 14, 1141-1151.	1.3	85
56	UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2012, 34, 671-679.	2.0	48
57	Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. Journal of Clinical Pharmacology, 2011, 51, 309-320.	2.0	55
58	The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease. Clinical Pharmacokinetics, 2011, 50, 1-24.	3.5	50
59	Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 2011, 40, 307-313.	3.4	55
60	Nonsteroidal Anti-Inflammatory Drugs May Reduce Enterohepatic Recirculation of Mycophenolic Acid in Patients With Childhood-Onset Systemic Lupus Erythematosus. Therapeutic Drug Monitoring, 2011, 33, 658-662.	2.0	14